AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06008951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to music
Description: All participants will listen to self-chosen or researcher-chosen music with noise-cancelling headphones (JBL Tune 770NC). The music will be administered for 20 minutes before participants receive increasing electric pain stimuli.
Study NCT06008951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listening to a podcast
Description: ln the control condition, participants will listen to a podcast with noise-cancelling headphones (JBL Tune 770NC). The podcast will be administered for 20 minutes before participants receive increasing electric pain stimuli.
Study NCT04935606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Care participants will receive their standard medical care as usual and all study assessments. Providers will not receive information about their drug use. To reduce Hawthorne effect biases and to mask the study's purpose, RAs will provide the Usual Care arm patients with a cancer screening booklet and have them view a cancer screening Video Doctor. Participants will receive re-contact calls (5 min) to provide attentional control for the Usual Care arm, motivate continued trial participation by reminding next research assessment and study incentives, update contact information, and address participation barriers, but do not provide intervention. At study end, Usual Care will receive the QUIT video doctor and drug use reduction booklet materials including overdose prevention materials and a list of clinic/community resources to help them reduce substance use.
Study NCT04935606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QUIT Intervention (doctor brief advice, video doctor, health coaching sessions at 2- and 6-weeks)
Description: QUIT's core components include:~1. patient screening with the WHO Alcohol Smoking and Substance Involvement Screening Test (ASSIST, score 4-26);~2. face-to-face brief clinician advice on reducing drug use (2-3 minutes);~3. video doctor reinforcing the clinician message;~4. drug use reduction brochure;~5. 2- and 6-week telephone health coaching sessions to enhance self-efficacy in reducing drug use, via motivational interviewing and cognitive behavior therapy (CBT) techniques (20-30 minutes).
Study NCT04935606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QUIT-Mobile (QUIT Intervention plus weekly mobile-web app or text message weekly self-monitoring, automated feedback over 12 months)
Description: The QUIT-Mobile intervention includes QUIT's core components and adds:~1. SMS/IVR/mobile-app self-monitoring survey prompts twice-weekly during the QUIT coaching through 6 weeks, and then weekly self-monitoring and automated feedback via SMS/IVR/app through 12-months.~2. Web-based dashboards will be used by coaches for monitoring of patients' self-monitoring data to enhance 2- and 6-week coaching sessions and for monitoring during the post-coaching self-management and monitoring period from 7-weeks to 12-months and intervening accordingly. The mobile platform will provide the same intervention functions (self-monitoring surveys and feedback messages) and robust data transfer protocols across three mobile technology platforms.
Study NCT05854966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI 613
Description: For INDUCTION therapy (14 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 14-day cycles for cycles 1 and 2 only.~For MAINTENANCE therapy (21 day cycles): Devimistat (CPI-613) 2,500mg/m2, days 1-5, 21-day cycles until progression, intolerable toxicity or withdrawal of consent.
Study NCT05854966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: For INDUCTION therapy (14 day cycles):~Metformin 500 mg daily (taken with meals), days 1-2 for cycle 1 only. Metformin 500 mg twice daily (taken with meals), days 3-14 for cycle 1 only. Metformin 1,000 mg daily (taken with meals), days 1-2 for cycle 2 only. Metformin 1,000 mg twice daily (taken with meals) days 3-4 for cycle 2 only.~For MAINTENANCE therapy (21 day cycles): Metformin 1,000 mg twice daily (taken with meals) days 1-21 until progression, intolerable toxicity or withdrawal of consent
Study NCT05854966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: In the first induction cycle ONLY, extra blood will be withdrawn on day 1 before and after treatment with CPI-613 research purposes. Additional blood draws on days 2-5 to test blood before receiving CPI-613 to make sure participants are healthy enough to receive CPI-613.
Study NCT05854966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow biopsy
Description: After the second induction cycle participants will have a bone marrow biopsy. After this biopsy, participants will have other bone marrow biopsies every 3 months for the next year. After the first year, participants may have a bone marrow biopsy if the treating physician feels it is necessary.
Study NCT06088823 — intervention group
Intervention type: OTHER
Intervention: Heart surgery
Description: Adult cardiac surgery
Study NCT06496620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Solrikitug low dose
Description: Solrikitug subcutaneous injection
Study NCT06496620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biological: Solrikitug high dose
Description: Solrikitug subcutaneous injection
Study NCT06496620 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT04872413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood, saliva or tissue sample collection
Study NCT04872413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-Up
Description: Undergo follow-up
Study NCT05974722 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OviTex Mesh
Description: Patient will receive Ovitex Mesh (TELA Bio)
Study NCT05974722 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pledgeted sutures
Description: Patient will receive pledgeted sutures
Study NCT05176899 — intervention group
Intervention type: DEVICE
Intervention: Use of Eko CORE electronic stethoscope
Description: Recording of heart sounds using electronic stethoscope
Study NCT05734768 — intervention group
Intervention type: BEHAVIORAL
Intervention: State-Trait Anxiety Inventory - Y ou STAI-Y
Description: Questionnaire
Study NCT04771455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss
Description: Participants will receive behavioral weight loss intervention
Study NCT04771455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention component: Decrease overvaluation of weight and shape
Description: Participants will receive an intervention component to decrease overvaluation of weight and shape
Study NCT04771455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention component: Decrease unhealthy weight control practices
Description: Participants will receive an intervention component to decrease unhealthy weight control practices
Study NCT04771455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention component: Decrease negative affect
Description: Participants will receive an intervention component to decrease negative affect
Study NCT06406751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MI Paste
Description: Sterile swabs will be used to collect plaque from under the subject's upper denture (when the denture is removed) and the subject's mouth tissues. This will be used for genomic DNA, bacteria analysis, and fungus analysis. Subjects will also apply 1 cubic centimeter of MI Paste to the fitting surface on a daily basis for 7 days. Afterward, subjects will return to the clinic for another sterile swab to be collected.
Study NCT06512584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PJ009
Description: subcutaneous injections, 0.05 mg/kg once daily
Study NCT06512584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PJ009 Placebo
Description: subcutaneous injections, once daily
Study NCT05162781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speed of Processing Training
Description: This training component targets cognitive processing speed, i.e., how quickly individuals process information that they receive through their senses. Cognitive processing speed is thought to be a basic capacity of the brain that underlies several other cognitive functions. Training is implemented using a web-based computer game, in which participants are required to fixate on a target at the center of the screen and identify targets in the periphery. The game is made progressively more difficult, in small increments, as participants gain mastery by increasing the speed at which targets are presented and increasing the number of distractors.
Study NCT05162781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed of Processing Training
Description: This training component targets cognitive processing speed, i.e., how quickly individuals process information that they receive through their senses. Cognitive processing speed is thought to be a basic capacity of the brain that underlies several other cognitive functions. Training is implemented using a web-based computer game, in which participants are required to fixate on a target at the center of the screen and identify targets in the periphery. The game is made progressively more difficult, in small increments, as participants gain mastery by increasing the speed at which targets are presented and increasing the number of distractors.
Study NCT05162781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instrumental Activities of Daily Living In-lab Training
Description: The training component is thought to bridge SOPT training, which targets a basic cognitive capacity, and IADL performance in daily life. This training component will involve repeated trials in which participants will practice carrying out simulated IADL tasks in the lab under the supervision of the trainer. The training will follow shaping principles, i.e., task requirements will be made progressively more challenging, in small increments, as participants gain mastery. Frequent, positive feedback will be provided.
Study NCT05162781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Transfer Packagke
Description: This training component is designed to transfer improvements in cognition from the treatment setting to everyday life. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning performance of IADL as homework.
Study NCT05162781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Caregiver Coaching
Description: One or more family members of the participant will receive coaching on how to best support the participant in carrying out the in-home components of the intervention.
Study NCT05162781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Caregiver Coaching
Description: One or more family members of the participant will receive coaching on how to best support the participant in carrying out the in-home components of the intervention.
Study NCT05162781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up Phone Calls
Description: After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis after.
Study NCT05162781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up Phone Calls
Description: After treatment ends, four phone calls will be placed once-a-week for four weeks, then once-a-month for 11 months. The follow-up calls will target transition of any changes achieved during treatment into everyday life on a long-term basis after.
Study NCT05162781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyle In-lab Training
Description: This training component is designed to promote lifestyle changes that support brain fitness. Participants will receive education and coaching in the lab on relaxation, healthy nutrition, and healthy sleep.
Study NCT05162781 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyle Transfer Package
Description: This training component is designed to support integration into everyday life of the lifestyle changes training in the lab. Elements of this package include negotiating a behavioral contract about the roles of the participant and family caregiver in the treatment, monitoring behavior outside the lab, and assigning relaxation exercises, for example, as homework.
Study NCT06093477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fast-Dissolve Melatonin Pill
Description: Participants in this arm will take 3mg of melatonin in fast-dissolve pill form daily during the specified study period.
Study NCT06093477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fast-Dissolve Placebo Pill
Description: Participants in this arm will take 3mg of placebo in fast-dissolve pill form daily during the specified study period.
Study NCT05062785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: This will be given intranasally at differing doses depending on study day. A total of 11 possible doses will be tested, ranging from 0 to 1000 U insulin. Each volunteer will come for 5 visits.~On the first treatment day participants will receive placebo (sterile water) in each nostril followed by a 4-hour observation period. After this observation period participants will receive the initial dose of insulin squirted in each nostril followed by a a 4 hour observation period. Participants will have at least 7 days in between the other 4 visits. Subsequent visits will include increased doses of insulin (depending on how this is tolerated) and will take approximately 4 hours at these visits.
Study NCT05491265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Kangaroo mother care
Description: Skin to skin contact between mother and preterm newborn between gestational age 28 weeks to 36+6 weeks for three sessions per day ,each contact session of two hours .
Study NCT06244628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Oral administration of Iguratimod, 25mg twice daily
Study NCT05223777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KINCISE
Description: The KINCISE™ Surgical Automated System (KINCISE) (DePuy Synthes Products, Inc, Warsaw, IN) was developed to replace the handheld mallet traditionally used in total hip arthroplasty (THA). The device is an FDA-approved medical instrument.
Study NCT05223777 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Handheld Mallet
Description: The handheld mallet traditionally used in total hip arthroplasty.
Study NCT04619979 — intervention group
Intervention type: PROCEDURE
Intervention: patients undergoing gynecological surgery under general anesthesia
Description: patients undergoing gynecological surgery under general anesthesia
Study NCT06432153 — intervention group
Intervention type: OTHER
Intervention: observation
Description: Participants who receive routine clinical care, without additional intervention from the study
Study NCT05578846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Participants will receive single Dose A dose of ALXN2050 tablet (3 × Dose B) orally under fasted conditions.
Study NCT05578846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Participant will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally under fasted conditions.
Study NCT06023563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality active video gaming using Nintendo switch sports
Description: Playing 2 pre-selected VR active video games from beach tennis, soccer, volleyball, badminton, bowling, and chambara for 10 minutes each with a 5 minute break in-between. Total duration 30-40 minutes.
Study NCT05578846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: Participants will receive single Dose A of ALXN2050 tablet (1 × Dose A) orally with a high-fat meal.
Study NCT06023563 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy balance exercises
Description: Balance exercises: Standing with feet together for 10 seconds 5 times, standing with 1 foot in front of other for 10 seconds 5 times on both sides, standing on one leg for 10 seconds 5 times on both sides, walking with one foot in front of other on a 1-meter-long line for 5 repetitions and standing on a balance board for 30 seconds for 3 repetitions. 5 minutes each of warm-up and cool down exercises. Total duration 20-30 minutes.
Study NCT06585241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273 Variant-containing Formulation
Description: Sterile liquid for injection
Study NCT04914299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based positive intelligence intervention
Description: A 6 weeks App-guided and support-group based positive intelligence cognitive behavioral intervention in addition to standard prenatal and postnatal care
Study NCT04914299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard prenatal and postnatal care(Providing psychoeducation and referral to psychotherapy or pharmacotherapy based on participant's symptoms).
Study NCT04914299 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard prenatal and postnatal care(Providing psychoeducation and referral to psychotherapy or pharmacotherapy based on participant's symptoms).
Study NCT03298243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation
Description: Non-invasive, computer-controlled miniature tendon vibrators, similar to those used in off-the-shelf activity monitors.
Study NCT06408974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: . Standard monitoring procedures will include pulse oximetry, electrocardiography, and noninvasive arterial pressure prior to anesthetic induction. All patients will be premedicate antibiotic prophylaxis, according to the hospital's protocol. Anesthesia will be induced with intrathecal bupivacaine 10mg and ,1 mg/kg ketamine added in group A under sterile condition
Study NCT06408974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: . Standard monitoring procedures will include pulse oximetry, electrocardiography, and noninvasive arterial pressure prior to anesthetic induction. All patients will be premedicate antibiotic prophylaxis, according to the hospital's protocol. Anesthesia will be induced with intrathecal bupivacaine 10mg and iv dexamethasone will be added
Study NCT05621577 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MANDIBULAR ADVANCEMENT DEVICE
Description: orthodontically treating obstructive sleep apnea
Study NCT05655741 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will be asked to complete a series of 3 questionnaires that will be used to gain insight into the current expert consensus for Genomic Bereavement care for Pregnancy Loss.~The 2nd and 3rd Questionnaire will be modified from the first to try to generate consensus, depending on the answers from the previous round.
Study NCT05096195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg/ml
Description: Details described in intervention arm/group description section.
Study NCT05096195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D prophylaxis
Description: Details described in intervention arm/group description section.
Study NCT05096195 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Monitoring of post-injection calcium and phosphate
Description: Details described in intervention arm/group description section.
Study NCT05216497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingavirin®, 90 mg capsules
Description: 90-180 mg/day for 7 days on top of standard therapy
Study NCT05216497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-2 capsules for 7 days on top of standard therapy
Study NCT05442905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Anesthesia will be induced with propofol 2-3mg/kg
Study NCT05442905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium Besylate
Description: Atracurium 0.15mg/kg used for muscle relaxation before intubation
Study NCT05442905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: sevoflurane(1%-2%) used during anesthesia
Study NCT04821687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ongentys 50mg
Description: Opicapone 50mg will be added to current and stable therapy of L-DOPA/DDCI
Study NCT04821687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Madopar Tab. 125 or Perkin Tab. 25-100mg
Description: Madopar Tab. 125 or Perkin Tab. 25-100mg will be added to current and stable therapy of L-DOPA/DDCI
Study NCT05188222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maltodextrin solution
Description: The oral preparation of 50 grams of Maltodextrin solution mixed in 400 mL of water
Study NCT05188222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Specifically formulated placebo to provide a similar taste and texture to Maltodextrin, without the same carbohydrate characteristics
Study NCT04696484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: coopeRATE Prompt
Description: The coopeRATE Prompt intervention is a set of two questions delivered to patients before the clinical encounter that elicit their concerns and goals. The intervention is delivered to patients online, outside the clinic setting.